top of page
    • Sep 12

London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study

CEO Tim Wilson describes the rationale for focusing on IgE, and why the company has chosen folate receptor alpha as its first target. This new fundraising brings total series B funds raised to £43.25 million.



Comentários

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE

bottom of page